Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

AstraZeneca vaccine doses found in Italy, export block on table - French official

World Mar 24, 2021 10:00AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. Italy resumes AstraZeneca COVID-19 vaccinations, in Turin 2/2

By Michel Rose, Francesco Guarascio and Giselda Vagnoni

PARIS (Reuters) -Some 29 million doses of AstraZeneca (NASDAQ:AZN) COVID-19 vaccines were found during an inspection at a plant in Italy over the weekend, a French official said on Wednesday, and checks are still needed to assess whether they were export-bound.

The news of the AstraZeneca doses "hidden" at a Catalent (NYSE:CTLT) factory in Anagni, near Rome, was first reported earlier on Wednesday by Italian newspaper La Stampa, which said the doses were found in an inspection by Italian authorities after a request from the European Commission.

The discovery may well deepen an EU standoff with AstraZeneca, which has slashed its supply targets to the bloc, and with Britain, which wants access to some AstraZeneca doses produced in the EU.

"An inspection took place this weekend at the Anagni plant and uncovered a stock of 29 million doses. The destination for these doses still needs to be clarified," the official at the French presidency said, noting that if doses were for export, they could be blocked.

An Italian official confirmed the inspection and said the doses were to be sent to Belgium. It is unclear whether from Belgium they could be exported or distributed across the EU.

The European Commission declined to comment on the doses at the Anagni factory. A spokesman for AstraZeneca did not reply to a request for comment. Catalent was not immediately available for comment.

An EU official said some of the doses at the Catalent plant might come from a vaccine factory in the Netherlands run by AstraZeneca's subcontractor Halix.

The Anagni plant is in charge of bottling AstraZeneca vaccines produced at the Halix factory and also at a plant in Belgium run by subcontractor Thermo Fisher Scientific (NYSE:TMO).

Both vaccine-making factories are listed in the contract AstraZeneca signed with the EU in August as suppliers to the EU.

However, the Halix factory has not yet been approved in the EU, as AstraZeneca did not submit sufficient data to the EU drugs regulator. Vaccines produced there cannot be used in the EU until that approval is received.

It is unclear why AstraZeneca did not seek earlier approval for the factory. The Anglo-Swedish drugmaker declined to comment on this.

Halix is also listed as a supplier for Britain, which is urging the EU to allow the shipment of doses produced there. Britain has so far exported no AstraZeneca vaccines to the EU, despite two UK plants being listed in the EU contract as suppliers for the bloc.

Halix said it started producing vaccines for the EU in December and has a capacity to produce about 5 million doses per month. The company declined to comment on the precise amount of vaccines it had already produced or on their destination.

AstraZeneca said earlier in March it would aim to deliver only 100 million doses to the EU by the end of June, instead of 300 million envisaged in its supply contract with the 27-nation bloc.

The EU blocked in early March a shipment of AstraZeneca vaccines to Australia saying the move was justified by the company's non-compliance with its contractual obligations with the EU.

AstraZeneca vaccine doses found in Italy, export block on table - French official
 

Related Articles

Russia scraps remaining COVID restrictions
Russia scraps remaining COVID restrictions By Reuters - Jul 01, 2022

(Reuters) - Russia said on Friday it was ending all restrictions to combat the spread of COVID-19, including the requirement to wear masks, citing a steady decline in deaths from...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Kaveh Sun
Kaveh Sun Mar 24, 2021 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Simply Eu does NOT want to pay. It approved vaccines make in india at cheaper price. If they dont approve Halix, there is no reason to stop them to ship to outside for higher price.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email